“Now we still have to gain some more share over the course of the year to come back to where we were pre the change to Alley.”

In context

“firmed today from the margin profiles and otherwise includes us absorbing that. Jeff Stewart: So I'll go over your market share, give you some flavor on that. And I'll focus on our two big markets, the US and China. So as I mentioned, we were right on our guidance, right on our forecast for the first quarter. Remember, biggest impact there was the price because we reversed the Alley [ph] redesign from last year. And so when we looked at basically what happened from the fourth quarter to the first quarter, we know we took a market share hit in toxins in that fourth quarter. The good news is we've seen a complete reengagement in the basically the old Alley program with all of our accounts. So things are quite stable. And we actually had a one market share point gain back from where we were. Now we still have to gain some more share over the course of the year to come back to where we were pre the change to Alley. So we have lost year-over-year some share in toxins. In the US in filler, our share is very, very stable. We did not see a significant share impact on the filler side of the business. It's just been sort of a double digit market pressure there. Now in China, I'm quite pleased with the share performance. We've recently had a couple of significant approvals sequentially. We have the masseter approval for BOTOX, which is sort of in the lower face and jawline and also VOLUX, which is in Juvederm. So we've actually seen significant positive momentum in BOTOX share in China as well as positive share in filler. So it's a little variable across the board. Our big push will be to recover that share over the course of the year in the US toxin space. Hope that helps. Operator: Next, we'll go to the”